Donor-Derived Mesenchymal Stem Cells Combined With Low-Dose Tacrolimus Prevent Acute Rejection After Renal Transplantation | Zendy

Yanwen Peng | Zendy; Ke Ming | Zendy; Lu Xu | Zendy; Longshan Liu | Zendy; Xiaoyong Chen | Zendy; Wenjie Xia | Zendy; Xiaobo Li | Zendy; Zhen Chen | Zendy; Junjie Ma | Zendy; Dehuai Liao | Zendy; Guanghui Li | Zendy; Jiali Fang | Zendy; Guanghui Pan | Zendy; Andy Peng Xiang | Zendy

Open Access

Donor-Derived Mesenchymal Stem Cells Combined With Low-Dose Tacrolimus Prevent Acute Rejection After Renal Transplantation

Author(s) -

Yanwen Peng,

Ke Ming,

Lu Xu,

Longshan Liu,

Xiaoyong Chen,

Wenjie Xia,

Xiaobo Li,

Zhen Chen,

Junjie Ma,

Dehuai Liao,

Guanghui Li,

Jiali Fang,

Guanghui Pan,

Andy Peng Xiang

Publication year - 2012

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/tp.0b013e3182754c53

Subject(s) - tacrolimus , medicine , calcineurin , transplantation , mesenchymal stem cell , immunosuppression , urology , kidney transplantation , population , kidney , renal function , surgery , gastroenterology , pathology , environmental health

The deleterious side effects of calcineurin inhibitors have impaired long-term survival after renal allograft. New immunotherapy regimens that minimize or even eliminate calcineurin inhibitors are required to improve transplantation outcome. Mesenchymal stem cells (MSCs) represent a unique cell population with immunosuppressive function and prolong allograft survival in experimental organ transplant models.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research